Petros Grivas· @PGrivasMDPhD · X·· 22 小时前评分70
正文 · 机器翻译
Dr. Bedke 和 @AndreaNecchi 提供的局限期 MIBC 重要数据：围手术期加用抗 PD-1 不优于单独使用新辅助 Gem/Cis；与 NIAGARA 数据不一致。围手术期 EV/ICI 联合方案已在 EV303/304 和 VOLGA 试验中显示出 EFS/OS 获益 @myESMO #ESMOAmbassadors #ESMO26 @OncoAlert
34 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-invasive #BladderCancer (#MIBC), as discussed by @y_loriot 🔗 https://ow.ly/TbzF50ZZ0s2 #InsightsbyESMO在 X 查看被引用的帖子
来源：Petros Grivas · x.com